Form 8-K

8-K — Lantern Pharma Inc.

Accession: 0001493152-26-043808

Filed: 2026-09-23

Period: 2026-09-23

CIK: 0001763950

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001763950

2026-09-23

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): September 23, 2026

Lantern

Pharma Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-39318

46-3973463

(State

or Other Jurisdiction

Incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

1920

McKinney Avenue, 7th Floor

Dallas,

Texas

75201

(Address

of Principal Executive Offices)

(Zip

Code)

(972)

277-1136

(Registrant’s

telephone number, including area code)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act: Common Stock

Title

of each class

Trading

Symbol

Name

of each exchange on which registered

Common

Stock, $0.0001 par value

LTRN

The

Nasdaq Stock Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure.

September 23, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release describing topics to be covered during

a live webinar hosted by the Company on September 23, 2026 to discuss Open-Medicine AI, a multi-agentic AI platform for drug development.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The

information in this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the

Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,

nor shall it be deemed incorporated by reference in any filings under the Securities Act of 1933, as amended, or the Exchange Act, regardless

of any general incorporation language in such filings, unless expressly incorporated by specific reference in such filing.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit

No.

Exhibit

Description

99.1

Press Release dated September 23, 2026 describing topics to be covered during a live webinar hosted by the Company on September 23, 2026 to discuss the Open-Medicine AI platform.

104

Cover

Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Lantern

Pharma Inc.,

Delaware Corporation

Dated:

September 23, 2026

By:

/s/

David R. Margrave

David

R. Margrave, Chief Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Open-Medicine

AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks,

Today at 12:30 PM ET

●

Management

will also discuss usage patterns, key future milestones, and an overview of the types of collaborations and partnerships under discussion

●

Investors,

collaborators, prospective partners, and interested parties are encouraged to register and see a live demonstration of the platform’s

key capabilities: Register Here

DALLAS

— September 23, 2026 — Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-native biopharma company using artificial

intelligence and genomic data to develop precision oncology therapies, will present the growth plan for Open-Medicine AI (OMAI) in a

live webinar today at 12:30 PM Eastern. Open Medicine AI is the company’s wholly owned subsidiary building a multi-agentic AI platform

for drug development. To register: https://us06web.zoom.us/webinar/register/9417895172347/WN_HNnjzsDuTjufesN-cdwaNw#/registration

CEO

Panna Sharma will lead the session and will be joined by the Chief Scientific Officer of Lantern Pharma and the Principal Architect of

the multi-agentic platform. OMAI’s core capabilities and initial platform were built inside Lantern’s own clinical programs

and areas of focus. The platform launched as withZeta.ai in April 2026, focused on rare cancers, and is now expanding into new diseases,

new types of therapies, and additional stages of drug development. Today’s session will show where OMAI is going, share feedback

from key user segments, and include a live demonstration of the platform’s most differentiated capabilities.

What

the Webinar Will Cover

●

Market:

The size of the opportunity and the shift from AI pilots to full-scale adoption in drug development.

●

Customers

& Feedback: Who is buying, what they need, how they use the platform; and what key customer segments and power users are

telling us.

●

Live

demo: The platform’s differentiated capabilities, shown in real time.

●

Roadmap:

Next generation of functionality and modules, priority disease areas, and key milestones including social and enterprise features.

●

Economics:

The subscription and enterprise licensing model.

●

Benchmarks:

How the platform performs and how performance is being measured.

●

Partnerships:

Types of collaborations and partnerships under discussion.

●

Shareholder

value: How OMAI adds to Lantern’s pipeline and long-term value.

Upcoming

Open-Medicine AI Webinar - www.lanternpharma.com

Webinar

Details

●

Date

and time: Today, Wednesday, September 23, 2026, 12:30 PM Eastern / 9:30 AM Pacific

●

https://us06web.zoom.us/webinar/register/9417895172347/WN_HNnjzsDuTjufesN-cdwaNw#/registration

●

Format:

45 minutes, including a presentation and live demo followed by Q&A. Questions can be sent in advance to IR@lanternpharma.com

●

Replay:

Available on the Investors section of www.lanternpharma.com after the event

About

Open Medicine AI

Open

Medicine AI is a wholly owned subsidiary of Lantern Pharma that is building a multi-agentic AI platform for end-to-end therapeutic development.

Its AI co-scientists were developed inside Lantern’s clinical-stage oncology programs and carry the data, constraints, and decision

points of real drug development — from target and biomarker selection through compound design, translational analysis, trial design,

and regulatory strategy. The OMAI platform was first commercialized as withZeta.ai, launched in April 2026 for rare and aggressive cancers,

and expanded in July 2026 with ZetaOmics™, a computational biology module released to early-access users. OMAI is extending this

architecture to additional disease categories, new therapeutic modalities, and the downstream challenges of drug development. The platform

is available to biopharma companies, research institutions, service providers, and drug developers through subscription and enterprise

licensing. For more information, visit www.open-medicine.ai.

About

Lantern Pharma

Lantern

Pharma (NASDAQ: LTRN) is a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence and

machine-learning platform to transform the cost, pace, and precision of oncology drug development. By integrating large-scale genomic

and biological data with advanced machine learning, RADR® is designed to identify the patients most likely to benefit from Lantern’s

therapies and to guide biomarker-driven clinical development. The company’s pipeline includes LP-184 (zirdafulven), LP-300, and

LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open Medicine AI. For

more information, visit www.lanternpharma.com.

Forward-Looking

Statements

This

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section

21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating

to: future events or our future financial performance; the expected market opportunity, user needs, platform roadmap, key future milestones,

expected economics, and commercial model for the Open-Medicine AI platform; plans for the performance, benchmarking, and differentiation

of the Open-Medicine AI platform; expectations relating to collaborations and partnerships; the planned evolution of the Open-Medicine

AI platform beyond withZeta.ai to target broader disease areas, new modalities, and additional real-world drug development challenges;

the planned development, value proposition and commercial potential of the Open-Medicine AI platform; and the potential advantages of

the Open-Medicine AI platform in identifying drug candidates, accelerating drug development, and generating revenue through software

licensing and subscription models.

Upcoming

Open-Medicine AI Webinar - www.lanternpharma.com

Any

statements that are not statements of historical fact (including, without limitation, statements that use words such as “anticipate,”

“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”

“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”

“target,” “model,” “objective,” “aim,” “upcoming,” “should,”

“will,” “would,” or the negative of these words or other similar expressions) should be considered forward-looking

statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by

the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required

to advance and support our existing and planned development programs and operations, (ii) the risk that our Open-Medicine AI commercialization

efforts may not generate the anticipated revenue or achieve the expected market adoption, (iii) the risk that implementation of our development

plans and new features for Open-Medicine AI may not be successful or may take longer than anticipated for development, completion, and

release, (iv) the risk that no drug product based on our proprietary AI platforms has received FDA marketing approval or otherwise been

incorporated into a commercial product, (v) the risk that benchmark or internal performance results for the Open-Medicine AI platform

may not be indicative of performance in other settings or in use by third parties, (vi) the risk that ongoing partnership and collaborations

discussions may not result in definitive agreements on acceptable terms or at all, and (vii) technical, scientific, regulatory, financial,

competitive, and operational risks and those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for

the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 30, 2026.

You

may access our Annual Report on Form 10-K for the year ended December 31, 2025 under the investor SEC filings tab of our website at www.lanternpharma.com

or on the SEC’s website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking

statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements

will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this

press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update

any forward-looking statements to conform the statement to actual results or changes in our expectations.

Media

& Investor Contacts

Lantern

Pharma — Investor Relations

Email:

IR@lanternpharma.com

Phone:

(972) 277-1136

Upcoming

Open-Medicine AI Webinar - www.lanternpharma.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (7118 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.3

Cover

Sep. 23, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 23, 2026

Entity File Number

001-39318

Entity Registrant Name

Lantern

Pharma Inc.

Entity Central Index Key

0001763950

Entity Tax Identification Number

46-3973463

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1920

McKinney Avenue

Entity Address, Address Line Two

7th Floor

Entity Address, City or Town

Dallas

Entity Address, State or Province

Entity Address, Postal Zip Code

75201

City Area Code

(972)

Local Phone Number

277-1136

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value

Trading Symbol

LTRN

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration